Results 41 to 50 of about 12,561 (177)

Evaluation of Treatment Safety in Patients with Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey Study: Design and Rationale

, 2022
Objective: Safety and effectiveness of edoxaban was demonstrated in phase III, Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE-AF-TIMI 48) trial and is being confirmed in ...
ÖZPELİT, EBRU, Turk, Ugur Onsel, Alioglu, Emin, De Caterina, Raffaele, Mavioglu, Zafer, Türk Uğur Önsel, Diker, Erdem, Zafer Mavioğlu, Caterina, Raffaele De, De Caterina R., Emin Alioğlu, Uğur Önsel Türk, Erdem Diker, Raffaele De Caterina, Mavioglu Z., Diker E., Ebru Özpelit, Alioglu E., Ozpelit E., Turk U. O., null null   +20 more
core   +1 more source

Inside the ‘Black Box’ of Pharmaceuticalisation: NICE, the Permissive Principle and the Case of Anticoagulants [PDF]

Sociol Health Illn
ABSTRACT Sociological interest in pharmaceuticalisation continues to grow, especially regarding the expansion of pharmaceutical use in society. This article presents the first major empirical study focusing on the directionality of pharmaceuticalisation by taking cost‐effectiveness assessment and regulation of anticoagulants in England by the National ...
Abraham J, Balendran G.
europepmc   +2 more sources

Edoxaban use in the context of dental procedures: analysis from the EMIT-AF/VTE database

BDJ Open, 2023
Introduction Literature reviews support continuing anticoagulation during dental procedures. However, studies often present grouped anticoagulation data, and information on individual anticoagulant management would be helpful to dentists.
Cathy Chen, Manish Saxena, Christian von Heymann, Thomas Vanassche, James Jin, Robert Lersch, Sabine Köhler, Amparo Santamaria, Martin Unverdorben, Paolo Colonna   +9 more
doaj   +1 more source

A Renal Function Based Trade-Off Analysis of Non-vitamin K Antagonist Oral Anticoagulants in Nonvalvular Atrial Fibrillation

Frontiers in Physiology, 2018
Background: Non-vitamin K antagonist oral anticoagulants (NOACs) depend on some degree of renal excretion, and no head-to-head comparisons based on renal function is available. This study mainly investigated the trade-off property of NOACs in nonvalvular
Ling-Yun Zhou, Shuo-Fei Yang, Zhen Zhang, Chi Zhang, Long Shen, Zhi-Chun Gu, Xiao-Cong Zuo   +6 more
doaj   +1 more source

Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation

Clinical and Applied Thrombosis/Hemostasis, 2020
Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use. As the main adverse event is bleeding, it is relevant whether edoxaban has additional effects on platelet function. We aimed to assess
Juraj Sokol MD, PhD, Frantisek Nehaj MD, Jela Ivankova RNDr, Michal Mokan MD, PhD, Lenka Lisa MD, PhD, Jana Zolkova RNDr, Lubica Vadelova RNDr, Marian Mokan Prof, MD, DSc, FRCP Edin, Jan Stasko Prof, MD, PhD   +8 more
doaj   +1 more source

Electronic monitoring of adherence to once‐daily and twice‐daily direct oral anticoagulants in patients with atrial fibrillation: Baseline data from the SMAAP‐AF trial

Journal of Arrhythmia, 2021
Background Nonadherence diminishes the efficacy of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (NVAF). This report presents the baseline survey results regarding medication adherence among NVAF patients who were ...
Tsuyoshi Shiga, Toshimi Kimura, Noritoshi Fukushima, Yuji Yoshiyama, Kazunori Iwade, Fumiaki Mori, Yoichi Ajiro, Shoji Haruta, Yuichiro Yamada, Emi Sawada, Nobuhisa Hagiwara, the SMAAP‐AF investigators   +11 more
doaj   +1 more source

Periinterventional Management of Edoxaban in Major Procedures: Results from the DRESDEN NOAC REGISTRY

, 2023
Background Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for venous thromboembolism (VTE) treatment or stroke prevention in atrial fibrillation.
Ulrike Hänsel, Laura Stannek, Jan Beyer-Westendorf, Evelyn Hammermüller, Christiane Naue, Sandra Marten, Luise Tittl, Christina Köhler, Kristina Fache, Marianne Spindler   +9 more
core   +1 more source

Clinical events with edoxaban in south Korean and Taiwanese atrial fibrillation patients in routine clinical practice [PDF]

, 2021
Edoxaban is approved for stroke prevention in nonvalvular atrial fibrillation (AF) patients in numerous countries. Outcome data are sparse on edoxaban treatment in AF patients from routine clinical practice, especially in Asian patients.
Kirchhof P., Wang C. -C., De Caterina R., Unverdorben M., Hwang G. -S., Chen C., Lin W. -S., Kim Y. -H., Choi E. -K., Chun-Chieh Wang, Wang, CC, Choi, EK, Kim, YH, Unverdorben, M, Eue-Keun Choi, Chen, C, Martin Unverdorben, De Caterina, R, Lin, WS, Raffaele De Caterina, Young-Hoon Kim, Kirchhof, P, Wei-Shiang Lin, Paulus Kirchhof, Cathy Chen, Hwang, GS, Gyo-Seung Hwang   +26 more
core   +2 more sources

Edoxaban for stroke prevention in Chinese patients with atrial fibrillation: 1-year follow-up of the ETNA-AF-China study

Frontiers in Pharmacology
IntroductionNon–vitamin K antagonist oral anticoagulants (NOACs) are the first-line therapy to prevent ischaemic stroke in patients with atrial fibrillation (AF).
Xueyuan Guo, Juan Du, Yuehui Yin, Heng Qi, Zhisheng Jia, Xiaojun Ji, Yuqing Zhang, Xue Liang, Bing Deng, Jieyun Liu, Juan Ma, Cangsang Song, Huifang Feng, Suxin Luo, Jingfeng Wang, Yongqi Xiao, Lun Li, Junyou Cui, Zheng Huang, Xiang Cheng, Yuan Yi, Mengqi Liu, Cathy Chen, Martin Unverdorben, Changsheng Ma   +24 more
doaj   +1 more source

Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban

Scientific Reports, 2023
Since SLCO1B1 encodes the uptake transporter OATP1B1, which can influence the pharmacokinetic and pharmacodynamic profiles of edoxaban, polymorphisms in SLCO1B1 may affect the edoxaban response.
Ji Min Han, Eun Jeong Jang, Jeong Yee, Tae-Jin Song, Dong-Hyeok Kim, Junbeom Park, Hye Sun Gwak   +6 more
doaj   +1 more source